Article Figures & Data
Figures
- Fig 1.
Comparison of lesion CNR between gadopentetate dimeglumine and gadobutrol. The mean CNR of enhancing lesions is significantly higher with gadobutrol.
- Fig 2.
A 63-year-old woman with lung cancer. Gadobutrol MR imaging shows more enhancing lesions than gadopentetate dimeglumine MR imaging (arrow in the right precentral gyrus). Retrospective review of gadopentetate dimeglumine images suggests the existence of a small nodule in the right precentral gyrus, but it is not definite. A thicker enhancing rim and prominent gadolinium spillage are seen on gadobutrol MR imaging (arrowheads).
- Fig 3.
A 60-year-old man with lung cancer. Gadobutrol MR imaging shows more enhancing lesions than gadopentetate dimeglumine MR imaging (arrows). There is no suspected lesion on gadopentetate dimegluimine MR imaging. Note the higher signal intensity of the thick enhancing rim (arrowheads). The interval between the 2 MR images is 60 hours.
In this issue
Jump to section
Related Articles
Cited By...
- Improving Treatment Options for Brain Metastases From ALK-Positive Non-Small-Cell Lung Cancer
- Gadolinium Contrast Agents for CNS Imaging: Current Concepts and Clinical Evidence
- Does Higher Gadolinium Concentration Play a Role in the Morphologic Assessment of Brain Tumors? Results of a Multicenter Intraindividual Crossover Comparison of Gadobutrol versus Gadobenate Dimeglumine (the MERIT Study)
- MR Imaging of Neoplastic Central Nervous System Lesions: Review and Recommendations for Current Practice